Evidence map›Paper›PMID 40734507›Full record

ArticleFuture oncology (London, England)2025

ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCC.

Guangmin Mao, Zhuocheng Xin, Qingsong Fan, Huijuan Zhu, Jinjun Ye, Long Zhou, Yufeng He, Benhua Xu, Cheng Chen, Zhijun Li and 21 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06190782 (Phase III Randomized-controlled Study of PD-1 Inhibitor Combined With Local Therapy in Patients With Oligometastatic Esophageal Squamous Cell Carcinoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06190782 phase3recruitingnot on this map

Phase III Randomized-controlled Study of PD-1 Inhibitor Combined With Local Therapy in Patients With Oligometastatic Esophageal Squamous Cell Carcinoma

TypeinterventionalSponsorFudan UniversityRan2022 to 2027Enrolled354ConditionsEsophageal Squamous Cell Carcinoma, Oligometastatic Disease, RadiotherapyArmsPD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Guangmin MaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhuocheng XinDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qingsong FanDepartment of General Practice, Changhai Community Healthcare Center, Shanghai, China.
Huijuan ZhuDepartment of Radiation Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jinjun YeDepartment of Radiation Oncology, Jiangsu Province Cancer Hospital, Nanjing, Jiangsu, China.
Long ZhouDepartment of Radiation Oncology, Xiangtan Central Hospital of Hunan Province, Xiangtan, Hunan, China.
Yufeng HeDepartment of Radiation Oncology, Dongtai People's Hospital, Dongtai, Jiangsu, China.
Benhua XuDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Cheng ChenDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Zhijun LiDepartment of Radiation Oncology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China.
Xiaowei GuDepartment of Radiation Oncology, Jiangyin People's Hospital of Jiangsu Province, Jiangyin, Jiangsu, China.
Xianfeng LiDepartment of Radiation Oncology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Xiaomin WangDepartment of Radiation Oncology, Anyang Tumor Hospital, Anyang, Henan, China.
Junjun GuoDepartment of Radiation Oncology, Shangxi Province Cancer Hospital, Nanjing, Shangxi, China.
Zhengyang XuDepartment of Tumor Chemoradiotherapy Center, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Peng WanDepartment of Tumor Chemoradiotherapy Center, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Yunxia ZhangDepartment of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Fuzheng ZhangDepartment of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Canhong HuangDepartment of Radiation Oncology, Nantong Cancer Hospital, Nantong, Jiangsu, China.
Qiong YiDepartment of Radiation Oncology, Nantong Cancer Hospital, Nantong, Jiangsu, China.
Jiangqiong HuangDepartment of Radiation Oncology, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, China.
Shixiong LiangDepartment of Radiation Oncology, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, China.
Junqiang ChenDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fuzhou, Fujian, China.
Yu LinDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fuzhou, Fujian, China.
Qingliang FangDepartment of Radiation Oncology, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yun ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dashan AiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongcheng ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shengnan HaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qi LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CLINICAL

trial registrationNCT06190782 (ClinicalTrials.gov).

Indexed as

Esophageal NeoplasmsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorChinaClinical Trials, Phase III as TopicFemaleHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment OutcomeImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorAnti-PD-1 immunotherapychemo-immunotherapyesophageal squamous cell carcinomaoligometastatic carcinomaradiotherapy

Identifiers

PMID40734507
PMCPMC12344800

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.